Exhibit 99.1
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
Montreal, Quebec December 21, 2023 Theratechnologies Inc. (Theratechnologies or
the Company) (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf prospectus with the
securities regulatory authorities of all the provinces of Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the SEC) on Form F-3.
The filing is made for the purpose of restoring the original financing capacity which was available to Theratechnologies under its
previous base shelf prospectus dated December 14, 2021 expiring on January 14, 2024.
Once the Canadian securities
regulatory authorities have issued a receipt for the final short form base shelf prospectus and the shelf registration statement becomes effective, these filings will, subject to securities regulatory requirements, provide for the potential offering
in Canada and the United States of up to an aggregate of US$100,000,000 of common shares, preferred shares, subscription receipts, warrants, debt securities and units from time to time over a 25-month period. These filings are intended to give the Company the flexibility to take advantage of financing opportunities when market conditions are favourable. The terms of such future offerings, if any, will be
established at the time of such offerings. At the time any of the securities covered by these filings are offered for sale, a prospectus supplement containing specific information about the terms of any such offering will be filed with applicable
Canadian securities regulatory authorities and the SEC.
The shelf registration statement filed with the SEC has not yet become
effective. No securities may be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there
be any offer, solicitation or sale of, securities in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
A copy of the preliminary base shelf prospectus will be available on our SEDAR+ profile at www.sedarplus.ca and a copy of the
corresponding shelf registration statement is available on EDGAR at www.sec.gov. Alternatively, a copy of such documents is available upon request by contacting the Companys Corporate Secretary at 2015 Peel Street, Suite 1100, Montreal,
Quebec, Canada, H3A 1T8, telephone: (514) 336-7800.
About Theratechnologies
Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative
therapies addressing unmet medical needs.